---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000010"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T01:01:41.272466+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M

## Summary
- Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
- Reported stockholders' deficit of $32.1M as of Sept 30, 2024 and losses in two of the three most recent fiscal years.
- Must submit a compliance plan by March 5, 2025; has until Aug 3, 2026 to regain compliance.
- If plan not accepted or fails, delisting proceedings will commence; shares will trade with ".BC" designation.
- No immediate impact on listing or business operations; company intends to submit a plan.

## SEC filing metadata
- accession: 0001837607-25-000010
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/0001837607-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/aeon-20250203x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000010
- JSON: https://secwatch.observer/filing/0001837607-25-000010.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000010.txt

## Source-grounded claims
- claim_id: 779b867826c64cec921b13b18bd35a95690fae92
  claim: AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
  evidence_excerpt: February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000010/0001837607-25-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.